CDCA7L Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | B3KTR5 |
Other Accession | Q96GN5 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Antigen Region | 290-317 aa |
Other Names | CDCA7L;HR1; JPO2; R1; Cell division cycle-associated 7-like protein; Cell division cycle-associated 7-like protein; Protein JPO2; Cell division cycle-associated 7-like protein; Transcription factor RAM2 |
---|---|
Target/Specificity | This CDCA7L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 290-317 amino acids from the C-terminal region of human CDCA7L. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | CDCA7L Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Plays a role in transcriptional regulation as a repressor that inhibits monoamine oxidase A (MAOA) activity and gene expression by binding to the promoter. Plays an important oncogenic role in mediating the full transforming effect of MYC in medulloblastoma cells. Involved in apoptotic signaling pathways; May act downstream of P38-kinase and BCL-2, but upstream of CASP3/caspase-3 as well as CCND1/cyclin D1 and E2F1.
References
Huang A., et al. Cancer Res. 65:5607-5619(2005).
Chen K., et al. J. Biol. Chem. 280:11552-11559(2005).
Cathomen T., et al. Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
Ota T., et al. Nat. Genet. 36:40-45(2004).
Scherer S.W., et al. Science 300:767-772(2003).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.